Bridgit Hawkins is an experienced agricultural technology commercialisation expert.
Bridgit Hawkins.
Lucidome Bio has appointed agricultural technology commercialisation expert Bridgit Hawkins as chairperson, strengthening its governance bench as the company advances its breakthrough methane-reducing vaccine towards global commercial development. The company was established by AgriZeroNZ, with the support of the New Zealand Agricultural Greenhouse Gas Research Centre, the Pastoral Greenhouse Gas Research Consortium and the New Zealand Government and consolidates New Zealand’s intellectual property, scientific talent and funding into a single high-growth venture.
Lucidome Bio chief executive David Aitken said: “We’ve built strong … foundations and are now focused on making technology breakthroughs, progressing regulatory pathways, and strengthening our commercial roadmap into the future. Bridgit has navigated this transition many times and understands how to balance bold thinking with tight execution. She is set to play a critical role in helping us move with clarity and intent.”
Hawkins brings deep experience in leading technology-driven companies from early concept phase through to scale and exit. As former founder and CEO of Regen Ltd, she is currently chief sustainability officer at farm management solution company CropX.
Hawkins’ work has spanned startup governance, capital raising, intellectual property strategy, commercial partnerships, and measuring climate tech impact for global clients. With a master’s degree in agricultural science, she has also completed executive training at Stanford University’s Graduate School of Business and founded Fields of Change, an initiative focused on industry-wide solutions to systemic agricultural challenges.
“Early-stage governance is very different to conventional business-as-usual. You’re dealing with high potential, limited resources, and a very fast-moving market. The skill is knowing where to focus – what truly matters – and how to use the resources you have to maximise their effect,” Hawkins explained.
Hawkins said what drew her to Lucidome Bio was a rare combination of breakthrough science, a purpose-led team, and a shared sense of urgency. “The impact potential is enormous, the science is sound, and the belief is real. Now we need to show the world we can execute.”
The appointment comes as Lucidome Bio gains growing international recognition, following its selection as a 2025 global finalist at the Animal Health, Nutrition and Technology Innovation Showcase in Boston where the company’s methane vaccine was recognised for its potential to transform livestock methane reduction at scale.
The technology targets methanogenic archaea – the microbes in a ruminant’s gut responsible for methane production – by priming the animal’s immune system to generate antibodies that reduce methanogen growth through a cost-effective vaccine. The result is a practical, science-backed solution that supports emission reductions without compromising animal health or productivity.
“In many parts of the world, feed additives or high-cost delivery systems simply aren’t viable. A vaccine levels the playing field – it’s scalable, cost-effective, and equitable and I look forward to ensuring Lucidome Bio gains traction both locally and on the global innovation stage,” concluded Hawkins.
This is supplied content and not commissioned or paid for by NBR.
